Unlock stock picks and a broker-level newsfeed that powers Wall Street.
NasdaqGS - Nasdaq Real Time Price USD

Fortrea Holdings Inc. (FTRE)

Compare
7.05
-0.50
(-6.62%)
At close: April 1 at 4:00:02 PM EDT
Loading Chart for FTRE
  • Previous Close 7.55
  • Open 7.53
  • Bid 7.01 x 300
  • Ask 7.09 x 300
  • Day's Range 7.01 - 7.55
  • 52 Week Range 7.01 - 40.57
  • Volume 2,062,970
  • Avg. Volume 1,781,260
  • Market Cap (intraday) 635.91M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -3.03
  • Earnings Date May 12, 2025 - May 16, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 12.05

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical services that provides development and consulting services to clinical pharmacology and clinical development spectrum. The company also offers delivery models that include full service, functional service provider, and hybrid service structures. In addition, it delivers phase I – IV clinical trial management, clinical pharmacology, and consulting services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

www.fortrea.com

15,500

Full Time Employees

December 31

Fiscal Year Ends

Recent News: FTRE

View More

Performance Overview: FTRE

Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

FTRE
62.20%
S&P 500 (^GSPC)
4.23%

1-Year Return

FTRE
82.38%
S&P 500 (^GSPC)
7.42%

3-Year Return

FTRE
78.71%
S&P 500 (^GSPC)
23.92%

5-Year Return

FTRE
78.71%
S&P 500 (^GSPC)
128.01%

Compare To: FTRE

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: FTRE

View More

Valuation Measures

Annual
As of 4/1/2025
  • Market Cap

    635.91M

  • Enterprise Value

    1.72B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.23

  • Price/Book (mrq)

    0.47

  • Enterprise Value/Revenue

    0.64

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -12.18%

  • Return on Assets (ttm)

    -1.77%

  • Return on Equity (ttm)

    -17.65%

  • Revenue (ttm)

    2.7B

  • Net Income Avi to Common (ttm)

    -271.5M

  • Diluted EPS (ttm)

    -3.03

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    118.5M

  • Total Debt/Equity (mrq)

    88.00%

  • Levered Free Cash Flow (ttm)

    421.85M

Research Analysis: FTRE

View More

Company Insights: FTRE

Research Reports: FTRE

View More

People Also Watch